Signaling Pathway News and Research

RSS

Scientists identify novel small molecules that block human tumor cell growth

Researchers from the Cancer Institute at NYU Langone Medical Center have identified three novel small molecules that interrupt a crucial cellular communication pathway that regulates many aspects of development and cancer.

15 Apr 2011

Pharmacological manipulation of DKK1, DKK2 can treat various vascular diseases

Angiogenesis, the development of new blood vessels, is required during embryonic development and wound healing, as well as during disease processes such as tumor growth. The signals that direct angiogensis are incompletely understood, but could represent novel targets for the development of therapies that promote or inhibit this process.

12 Apr 2011

Johns Hopkins scientists identify autism gene linked to severity of social interaction deficits

With the help of two sets of brothers with autism, Johns Hopkins scientists have identified a gene associated with autism that appears to be linked very specifically to the severity of social interaction deficits.

7 Apr 2011

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.

5 Apr 2011

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Eli Lilly and Company announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer. The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.

5 Apr 2011

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Oncothyreon Inc. today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase, at the American Association of Cancer Research meeting in Orlando, Florida.

4 Apr 2011

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Scientists uncover genetic characteristic of metastatic prostate cancer

Scientists have uncovered a genetic characteristic of metastatic prostate cancer that defines a rare sub-type of this disease. These findings are published in Cancer Discovery, the newest journal of the American Association for Cancer Research, which will debut at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Breast cancer genome reveals potential therapeutic targets

Scientists have sequenced the entire genomes of tumors from 50 breast cancer patients and found more than 1,700 gene mutations, most of which were unique to individual patients. The researchers at Washington University in St. Louis and the Siteman Cancer Center suggest that this variability and uniqueness made it difficult to predict outcomes of the cases.

3 Apr 2011

New signaling pathway discovery sheds light on chronic dermatitis

A new signaling pathway, which is important for the regulation of the immune response and inflammation, was discovered by an international team of scientists led by prof Ivan Dikic from the Goethe University, Frankfurt, Germany.

1 Apr 2011

Molecular Templates ETB preclinical data against cancer to be presented at AACR meeting

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of small biologic therapies called Engineered Toxin Bodies, announced today that it will present preclinical data in two poster presentations at the 102nd American Association for Cancer Research annual meeting in Orlando, FL during April 2-6, 2011.

31 Mar 2011

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

The American Association for Cancer Research is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research.

28 Mar 2011

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Genentech, a member of the Roche Group, today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal cell carcinoma (aBCC), a particularly severe and debilitating form of skin cancer.

21 Mar 2011

Study sheds light on how vitamin A contributes to immune responses in gastrointestinal tract

Although it has been known for some time that vitamin A deficiency is linked with an impaired ability to resist infections, exactly how vitamin A and its metabolites contribute to the immune response is not well understood.

18 Mar 2011

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc. announced today that they have entered into an agreement to develop and commercialize FivePrime's FP-1039 product for multiple cancers.

17 Mar 2011

BRAF gene defect leads to pilocytic astrocytoma in children

Pilocytic astrocytoma, the most common brain tumor in children, is usually slow-growing and benign. However, surgeons often cannot completely remove the diffusely growing tumor.

16 Mar 2011

New research: Fzd9 receptor can stimulate bone formation

New research shows that the Wnt receptor Frizzled-9 promotes bone formation, providing a potential new target for the treatment of osteoporosis. The study appears online on March 14 in The Journal of Cell Biology.

15 Mar 2011

New animal model helps define molecular processes that lead to PA

Pilocytic astrocytoma is the most common pediatric brain tumor, and there are few medical therapies available to those patients for whom surgery is not curative.

15 Mar 2011

New research: Rhodopsin pigment in Drosophila may detect temperature

New research from Mount Sinai School of Medicine has discovered that rhodopsin, a pigment of the retina that is responsible for the first events in the perception of light, may also be involved in temperature sensation. This detection had not been revealed in previous studies.

14 Mar 2011

Study sheds light on how signals from CSF help drive neural development

Cerebrospinal fluid, the fluid found in and around the brain and spinal cord, may play a larger role in the developing brain than previously thought, according to researchers at Children's Hospital Boston.

11 Mar 2011

Signaling Pathway News and Research

Scientists identify novel small molecules that block human tumor cell growth

Pharmacological manipulation of DKK1, DKK2 can treat various vascular diseases

Johns Hopkins scientists identify autism gene linked to severity of social interaction deficits

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Oncothyreon's ONT-10, PX-866 preclinical data presented at AACR meeting

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

Scientists uncover genetic characteristic of metastatic prostate cancer

Breast cancer genome reveals potential therapeutic targets

New signaling pathway discovery sheds light on chronic dermatitis

Molecular Templates ETB preclinical data against cancer to be presented at AACR meeting

Scientists receive CFCF-AACR grants for carcinoid, pancreatic neuroendocrine tumor research

Genentech's vismodegib Phase II clinical study in advanced basal cell carcinoma meets primary endpoint

Study sheds light on how vitamin A contributes to immune responses in gastrointestinal tract

HGSI, FivePrime enter agreement to develop, commercialize FP-1039 for multiple cancers

BRAF gene defect leads to pilocytic astrocytoma in children

New research: Fzd9 receptor can stimulate bone formation

New animal model helps define molecular processes that lead to PA

New research: Rhodopsin pigment in Drosophila may detect temperature

Study sheds light on how signals from CSF help drive neural development

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News